Male Breast Cancer: Reevaluate Our Opinion

Male breast cancers (MBCs) are relatively uncommon malignancy with less than 1% incidence. MBC presents at a later age with a more advanced presentation as compared to the female breast cancer. Due to the paucity of the number of cases and trials regarding the MBC, female breast cancer treatment pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kale, Santosh, Rammohan, Rajmohan, Vas, Vilma, Elsayad, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026701/
https://www.ncbi.nlm.nih.gov/pubmed/32089923
http://dx.doi.org/10.1155/2020/6245415
_version_ 1783498735132606464
author Kale, Santosh
Rammohan, Rajmohan
Vas, Vilma
Elsayad, Chris
author_facet Kale, Santosh
Rammohan, Rajmohan
Vas, Vilma
Elsayad, Chris
author_sort Kale, Santosh
collection PubMed
description Male breast cancers (MBCs) are relatively uncommon malignancy with less than 1% incidence. MBC presents at a later age with a more advanced presentation as compared to the female breast cancer. Due to the paucity of the number of cases and trials regarding the MBC, female breast cancer treatment protocols are applied. Mastectomy and hormonal therapy remains the mainstay of treatment. Moreover, the data about prognosis of MBC remains limited.
format Online
Article
Text
id pubmed-7026701
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-70267012020-02-21 Male Breast Cancer: Reevaluate Our Opinion Kale, Santosh Rammohan, Rajmohan Vas, Vilma Elsayad, Chris Case Rep Oncol Med Case Report Male breast cancers (MBCs) are relatively uncommon malignancy with less than 1% incidence. MBC presents at a later age with a more advanced presentation as compared to the female breast cancer. Due to the paucity of the number of cases and trials regarding the MBC, female breast cancer treatment protocols are applied. Mastectomy and hormonal therapy remains the mainstay of treatment. Moreover, the data about prognosis of MBC remains limited. Hindawi 2020-02-06 /pmc/articles/PMC7026701/ /pubmed/32089923 http://dx.doi.org/10.1155/2020/6245415 Text en Copyright © 2020 Santosh Kale et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kale, Santosh
Rammohan, Rajmohan
Vas, Vilma
Elsayad, Chris
Male Breast Cancer: Reevaluate Our Opinion
title Male Breast Cancer: Reevaluate Our Opinion
title_full Male Breast Cancer: Reevaluate Our Opinion
title_fullStr Male Breast Cancer: Reevaluate Our Opinion
title_full_unstemmed Male Breast Cancer: Reevaluate Our Opinion
title_short Male Breast Cancer: Reevaluate Our Opinion
title_sort male breast cancer: reevaluate our opinion
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026701/
https://www.ncbi.nlm.nih.gov/pubmed/32089923
http://dx.doi.org/10.1155/2020/6245415
work_keys_str_mv AT kalesantosh malebreastcancerreevaluateouropinion
AT rammohanrajmohan malebreastcancerreevaluateouropinion
AT vasvilma malebreastcancerreevaluateouropinion
AT elsayadchris malebreastcancerreevaluateouropinion

Ejemplares similares